OATP1A2 and OATP2B1 Are Interacting with Dopamine-Receptor Agonists and Antagonists
- 28 April 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 17 (6), 1987-1995
- https://doi.org/10.1021/acs.molpharmaceut.0c00159
Abstract
Interaction with the dopaminergic system in the central nervous system is either therapeutically intended or it is a side effect. In both cases, dopamine receptor agonists (DRA) like the ergoline derivative bromocriptine and dopamine receptor antagonists (DRAn) like metoclopramide have to cross the blood brain barrier (BBB). The organic anion transporting polypeptides (OATP) 1A2 and 2B1 are cellular uptake carriers for a variety of endogenous and xenobiotic compounds. As both transporters are expressed in endothelial cells of the BBB, the aim of the present study was to determine, whether the DRA bromocriptine, cabergoline and pergolide and the DRAn metoclopramide and domperidone are interacting with OATP1A2 and 2B1 and could therefore be candidate genes modifying wanted and unwanted effects of these drugs. Localization of both transporters in the brain was confirmed using LC-MS/MS and immunofluorescence stainings. For the functional studies MDCKII cells stably expressing OATP1A2 or 2B1 were used. Initial interaction studies with the well-characterized transporter substrate estrone 3-sulfate revealed that all tested compounds except pergolide inhibit transport function of both proteins with the most potent effect for bromocriptine (IC50=2.2 µM (OATP1A2) and IC50=2.5 µM (OATP2B1)). Further studies using the indirect competitive counterflow method identified bromocriptine, cabergoline and domperidone as substrates of both transporters, whereas metoclopramide was only transported by OATP1A2. These findings were verified for domperidone by direct measurements using its tritium labeled form as tracer. Moreover, the transporter-mediated uptake of this compound was sensitive to the OATP1A2 and OATP2B1 inhibitor naringin. In conclusion, this study suggests that OATP1A2 and 2B1 may play a role in the uptake of active DR agonists and antagonists into the brain.Keywords
Funding Information
- Universit?t Basel
This publication has 50 references indexed in Scilit:
- Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorptionBiopharmaceutics & Drug Disposition, 2013
- Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of StatinsCirculation Research, 2010
- Structure and function of the blood–brain barrierNeurobiology of Disease, 2010
- Impact of OATP transporters on pharmacokineticsBritish Journal of Pharmacology, 2009
- Human Platelets Express Organic Anion-Transporting Peptide 2B1, an Uptake Transporter for AtorvastatinDrug Metabolism and Disposition, 2009
- ABCC Drug Efflux Pumps and Organic Anion Uptake Transporters in Human Gliomas and the Blood-Tumor BarrierCancer Research, 2005
- Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2)Online Journal of Public Health Informatics, 2005
- CITRUS JUICES INHIBIT THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-BDrug Metabolism and Disposition, 2005
- Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokineticsAlimentary Pharmacology & Therapeutics, 2004
- Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin ABiopharmaceutics & Drug Disposition, 2003